HBsAg＞3000 IU/mL慢性乙型肝炎非优势人群临床治愈2例报告

黄燕; 张琼月; 罗二平; 赵卫峰; 甘建和

doi:10.3969/j.issn.1001-5256.2022.07.027

HBsAg＞3000 IU/mL慢性乙型肝炎非优势人群临床治愈2例报告

DOI: 10.3969/j.issn.1001-5256.2022.07.027

苏州大学附属第一医院感染病科，江苏苏州 215000

基金项目:

国家“十三五”科技重大专项课题 (2017ZX10203201-002-002)

伦理学声明：本报告所有患者均已知情同意。

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：黄燕、罗二平负责课题设计，资料分析，撰写论文；黄燕、张琼月参与收集数据，修改论文；甘建和、赵卫峰负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
甘建和，ganjianhe@suda.edu.com

计量
- 文章访问数: 775
- HTML全文浏览量: 288
- PDF下载量: 69
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-10
- 录用日期: 2021-11-01
- 出版日期: 2022-07-20

Clinical cure of the non-dominant population in chronic hepatitis B patients with HBsAg>3000 IU/mL: A report of two cases

Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China

Research funding:

National Science and Technology Major Project during the 13th Five-Year Plan Period (2017ZX10203201-002-002)

More Information

Corresponding author: GAN Jianhe, ganjianhe@suda.edu.cn(ORCID: 0000-0002-1288-0178)

摘要

- 乙型肝炎, 慢性 /
- 干扰素α-2b /
- 临床治愈
- Hepatitis B, Chronic /
- Interferon Alfa-2b /
- Clinical Cure

HTML全文

图 1 患者NUC联合PEG-IFNα-2b治疗方案及HBsAg、HBeAg、抗-HBs血清学变化

Figure 1. NUC combined with PEG-IFNα-2b treatment regimen and serological changes of HBsAg, HBeAg, anti-HBs

下载: 全尺寸图片幻灯片

图 2 患者PEG-IFNα-2b治疗及HBsAg、抗-HBs血清学变化

Figure 2. PEG-IFNα-2b treatment and serological changes of HBsAg and anti-HBs

下载: 全尺寸图片幻灯片

参考文献(22)

[1]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[2]	Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on clinical cure (functional cure) of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.
[3]	CHAN H, CHAN F, HUI AJ, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study[J]. J Viral Hepat, 2019, 26(1): 126-135. DOI: 10.1111/jvh.13000.
[4]	HU P, SHANG J, ZHANG WH, et al. HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study[J]. Chin J hepatol, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005. 胡鹏, 尚佳, 张文宏, 等. 核苷(酸)类似物治疗部分应答的乙型肝炎患者通过聚乙二醇干扰素α-2a治疗获得HBsAg消失: New Switch研究[J]. 中华肝脏病杂志, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005.
[5]	HOU JL, WEI L, WANG GQ, et al. Chinical cure of hepatitis B: consensus and controversy[J]. Chin J hepatol, 2020, 28(8): 636-639. DOI: 10.3760/cma.j.cn501113-20200722-00409. 侯金林, 魏来, 王贵强, 等. 乙型肝炎临床治愈: 共识与争议[J]. 中华肝脏病杂志, 2020, 28(8): 636-639. DOI: 10.3760/cma.j.cn501113-20200722-00409.
[6]	HAN MF, WU D, TAN DM, et al. Combination/Sequential Therapy with ETV, Peg-IFN alpha-2b and GMCSF Enhanced HBsAg Loss and Appearance of HBsAb in NA Suppressed CHB Patients (the Anchor A Study): An Interim Analysis[C]. AASLD. Washington, 2017.
[7]	WU FP, YANG Y, LI M, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen≤1500 IU/mL: An observational study[J]. World J Gastroenterol, 2020, 26(13): 1525-1539. DOI: 10.3748/wjg.v26.i13.1525.
[8]	JIN Y, HUANG CY, WEI FL, et al. Combination therapy in HBeAg-positive chronic hepatitis B patients with poor virological response/HBV resistance to NAs[J]. Infect Dis Info, 2015, 28(5): 273-278. DOI: 10.3969/j.issn.1007-8134.2015.05.005. 金怡, 黄春洋, 魏飞力, 等. 联合治疗策略在应答不佳/耐药HBeAg阳性慢性乙型肝炎患者中的临床研究[J]. 传染病信息, 2015, 28(5): 273-278. DOI: 10.3969/j.issn.1007-8134.2015.05.005.
[9]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[10]	LI M, ZHANG L, LU Y, et al. Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferon α-2a[J]. Virol Sin, 2021, 36(2): 311-320. DOI: 10.1007/s12250-020-00290-7.
[11]	MA Y, WANG J, XIONG F, et al. Extended duration therapy regimens based on Pegylated interferon for chronic hepatitis B patients focusing on hepatitis B surface antigen loss: A systematic review and meta-analysis[J]. Infect Genet Evol, 2020, 85: 104492. DOI: 10.1016/j.meegid.2020.104492.
[12]	BAO X, GUO J, XIONG F, et al. Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs[J]. Int J Infect Dis, 2020, 96: 562-566. DOI: 10.1016/j.ijid.2020.05.041.
[13]	LAMPERTICO P, MESSINGER D, CORNBERG M, et al. A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B[J]. Ann Gastroenterol, 2018, 31(6): 712-721. DOI: 10.20524/aog.2018.0300.
[14]	CAO W, LI M, ZHANG L, et al. The characteristics of natural killer cells in chronic hepatitis B patients who received PEGylated-interferon versus entecavir therapy[J]. Biomed Res Int, 2021, 2021: 2178143. DOI: 10.1155/2021/2178143.
[15]	WANG JY, LI TJ, FU H, et al. Clinical and immunological characteristics of rapid decline of HBsAg at early stage of anti-HBV treatment with peginterferon[J]. Chin J Infect Chemother, 2021, 21(5): 557-565. DOI: 10.16718/j.1009-7708.2021.05.010. 王嘉悦, 李天驹, 付豪, 等. 聚乙二醇干扰素治疗慢性乙型病毒性肝炎早期HBsAg快速下降的临床及免疫学特征研究[J]. 中国感染与化疗杂志, 2021, 21(5): 557-565. DOI: 10.16718/j.1009-7708.2021.05.010.
[16]	MARCELLIN P, AHN SH, MA X, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J]. Gastroenterology, 2016, 150(1): 134-144. e10. DOI: 10.1053/j.gastro.2015.09.043.
[17]	HAN M, JIANG J, HOU J, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α 2a: 1 year follow-up of the OSST study[J]. Antivir Ther, 2016, 21(4): 337-344. DOI: 10.3851/IMP3019.
[18]	SUN J, DING H, CHEN G, et al. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China[J]. BMC Gastroenterol, 2019, 19(1): 65. DOI: 10.1186/s12876-019-0981-5.
[19]	LEE SK, KWON JH, LEE SW, et al. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B[J]. Liver Int, 2021, 41(2): 288-294. DOI: 10.1111/liv.14701.
[20]	REN P, CAO Z, MO R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk[J]. Expert Opin Biol Ther, 2018, 18(10): 1085-1094. DOI: 10.1080/14712598.2018.1518423.
[21]	LI SY, LI H, XIONG YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study[J]. J Viral Hepat, 2017, 24(Suppl 1): 12-20. DOI: 10.1111/jvh.12755.
[22]	DONG Y, LI M, ZHU S, et al. De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected paediatric patients with advanced fibrosis[J]. J Viral Hepat, 2020, 27(12): 1338-1343. DOI: 10.1111/jvh.13372.